[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp. (PHIO), reported acquisition of 23,000 shares of common stock represented by restricted stock units on 09/11/2025. The RSUs vest on the first annual anniversary of the grant and the reported beneficial ownership following the transaction is 38,666 shares, which includes shares underlying unvested RSUs. The filing notes the reported share totals were adjusted for prior reverse stock splits. The disclosure was submitted on a Form 4 by a single reporting person and includes a power of attorney exhibit.
Robert L. Ferrara, un direttore di Phio Pharmaceuticals Corp. (PHIO), ha riferito l'acquisizione di 23.000 azioni ordinarie rappresentate da restricted stock units il 11/09/2025. Le RSU vestoiscono al primo anniversario annuale della concessione e la proprietà beneficiaria riportata dopo la transazione è di 38.666 azioni, che includono azioni sottostanti RSU non vestite. La comunicazione nota che i totali azionari riportati sono stati adeguati in seguito a precedenti frazionamenti azionari inversi. La dichiarazione è stata presentata tramite Modulo 4 da una sola persona responsabile e comprende una relativa appendice di procura.
Robert L. Ferrara, un director de Phio Pharmaceuticals Corp. (PHIO), informó la adquisición de 23.000 acciones ordinarias representadas por unidades de acciones restringidas en 09/11/2025. Las RSU vencen en el primer aniversario anual de la concesión y la titularidad beneficiosa reportada tras la operación es de 38.666 acciones, incluidas las acciones subyacentes a RSU no adquiridas. La presentación señala que los totales de acciones reportados se ajustaron por previamente realizados desdoblamientos de acciones inversos. La declaración fue presentada en un Formulario 4 por una única persona reportante e incluye un anexo de poder notarial.
Phio Pharmaceuticals Corp.의 이사인 Ferrara Robert L.이 2025년 9월 11일에 제한된 주식단위(RSU)로 표시된 23,000주의 보통주를 취득했다고 보고했습니다. RSU는 부여의 첫 번째 연차 기념일에 vesting되며, 거래 후 보고된 수혜소유 지분은 미 vesting RSU가 포함된 38,666주입니다. 공시는 보고된 주식 총계가 이전의 역분할에 따라 조정되었다고 명시합니다. 이 공시는 단일 보고자에 의해 Form 4로 제출되었으며 위임장 부록을 포함합니다.
Robert L. Ferrara, administrateur de Phio Pharmaceuticals Corp. (PHIO), a fait état de l'acquisition de 23 000 actions ordinaires représentées par des unités d'actions restreintes le 11/09/2025. Les RSU vestent au premier anniversaire annuel de l'octroi et la propriété bénéficiaire déclarée après la transaction est de 38 666 actions, incluant les actions sous-jacentes aux RSU non acquises. Le dépôt indique que les totaux d'actions déclarés ont été ajustés pour des divisions inverses d'actions antérieures. La divulgation a été soumise sur un formulaire Form 4 par une seule personne déclarante et comprend une pièce annexe de procuration.
Robert L. Ferrara, ein Direktor von Phio Pharmaceuticals Corp. (PHIO), berichtete über den Erwerb von 23.000 Stammaktien, vertreten durch Restricted Stock Units, am 11.09.2025. Die RSUs vesten am ersten jährlichen Jahrestag der Gewährung, und die nach der Transaktion berichtete wirtschaftliche Eigentümerschaft beläuft sich auf 38.666 Aktien, einschließlich der unvesteten RSUs. Die Einreichung erwähnt, dass die gemeldeten Aktienbeträge aufgrund früherer Reverse-Stock-Splits angepasst wurden. Die Offenlegung wurde auf einem Formular 4 von einer einzelnen meldenden Person eingereicht und enthält eine Vollmachtsbeilage.
روبرت ل. فيرارا، مدير في شركة فايـو فارماسيوتيكلز (PHIO)، أبلغ عن شراء 23,000 سهم عادي ممثلة بوحدات أسهم مقيدة في 09/11/2025. تستحق RSU في السنة الأولى من تاريخ المنحة، وتبلغ الملكية المستفيدة المعلنة بعد الصفقة 38,666 سهمًا، بما في ذلك الأسهم الكامنة وراء RSU غير المستحقة. ي notes أن إجمالي الأسهم المعلن عنها قد تم تعديله بسبب تقسيمات الأسهم العكسية السابقة. تم تقديم الإفصاح عبر نموذج 4 من قِبل شخص واحد مُبلغ، ويشمل ملحق تفويض السلطة.
Robert L. Ferrara，Phio Pharmaceuticals Corp.（PHIO）的董事，报告于2025年9月11日收购了由受限股票单位（RSU）代表的23,000股普通股。 RSU将在授予后的第一个年度周年日归属，交易后所报告的受益所有权为38,666股，其中包括尚未归属的RSU所对应的股票。披露指出，报告的股票总数已根据以往的反向股票分割进行了调整。该披露通过一名申报人提交的Form 4提交，并包含一份授权书附件。
- Acquisition of 23,000 RSUs that will vest in one year, indicating alignment of director compensation with shareholder value
- Post-transaction beneficial ownership of 38,666 shares, showing the director holds both vested and unvested equity
- Shares are unvested (restricted stock units) and therefore not immediately transferable or a source of immediate liquidity
- No information on company size or total outstanding shares is provided, so the materiality of the award relative to capitalization cannot be determined from this filing
Insights
TL;DR: Director received RSUs that vest after one year, aligning compensation with long-term ownership.
This transaction is a routine director equity grant: 23,000 restricted stock units that convert to common shares on the first anniversary of the grant. Such awards are commonly used to retain directors and align their interests with shareholders. The post-transaction beneficial ownership is 38,666 shares, and the filing discloses adjustments for prior reverse splits. There are no indications of dispositions or derivative activity in this Form 4.
TL;DR: Transaction appears immaterial to capital structure absent company size context; it is a standard insider grant.
The Form 4 reports a non-derivative acquisition coded as an award of restricted stock units totaling 23,000 shares at $0 price, which will vest on the first anniversary. The report lists 38,666 shares beneficially owned after the grant, including unvested RSUs. The filing includes a remark that share counts were adjusted for prior reverse stock splits. No cash consideration or option exercise is shown.
Robert L. Ferrara, un direttore di Phio Pharmaceuticals Corp. (PHIO), ha riferito l'acquisizione di 23.000 azioni ordinarie rappresentate da restricted stock units il 11/09/2025. Le RSU vestoiscono al primo anniversario annuale della concessione e la proprietà beneficiaria riportata dopo la transazione è di 38.666 azioni, che includono azioni sottostanti RSU non vestite. La comunicazione nota che i totali azionari riportati sono stati adeguati in seguito a precedenti frazionamenti azionari inversi. La dichiarazione è stata presentata tramite Modulo 4 da una sola persona responsabile e comprende una relativa appendice di procura.
Robert L. Ferrara, un director de Phio Pharmaceuticals Corp. (PHIO), informó la adquisición de 23.000 acciones ordinarias representadas por unidades de acciones restringidas en 09/11/2025. Las RSU vencen en el primer aniversario anual de la concesión y la titularidad beneficiosa reportada tras la operación es de 38.666 acciones, incluidas las acciones subyacentes a RSU no adquiridas. La presentación señala que los totales de acciones reportados se ajustaron por previamente realizados desdoblamientos de acciones inversos. La declaración fue presentada en un Formulario 4 por una única persona reportante e incluye un anexo de poder notarial.
Phio Pharmaceuticals Corp.의 이사인 Ferrara Robert L.이 2025년 9월 11일에 제한된 주식단위(RSU)로 표시된 23,000주의 보통주를 취득했다고 보고했습니다. RSU는 부여의 첫 번째 연차 기념일에 vesting되며, 거래 후 보고된 수혜소유 지분은 미 vesting RSU가 포함된 38,666주입니다. 공시는 보고된 주식 총계가 이전의 역분할에 따라 조정되었다고 명시합니다. 이 공시는 단일 보고자에 의해 Form 4로 제출되었으며 위임장 부록을 포함합니다.
Robert L. Ferrara, administrateur de Phio Pharmaceuticals Corp. (PHIO), a fait état de l'acquisition de 23 000 actions ordinaires représentées par des unités d'actions restreintes le 11/09/2025. Les RSU vestent au premier anniversaire annuel de l'octroi et la propriété bénéficiaire déclarée après la transaction est de 38 666 actions, incluant les actions sous-jacentes aux RSU non acquises. Le dépôt indique que les totaux d'actions déclarés ont été ajustés pour des divisions inverses d'actions antérieures. La divulgation a été soumise sur un formulaire Form 4 par une seule personne déclarante et comprend une pièce annexe de procuration.
Robert L. Ferrara, ein Direktor von Phio Pharmaceuticals Corp. (PHIO), berichtete über den Erwerb von 23.000 Stammaktien, vertreten durch Restricted Stock Units, am 11.09.2025. Die RSUs vesten am ersten jährlichen Jahrestag der Gewährung, und die nach der Transaktion berichtete wirtschaftliche Eigentümerschaft beläuft sich auf 38.666 Aktien, einschließlich der unvesteten RSUs. Die Einreichung erwähnt, dass die gemeldeten Aktienbeträge aufgrund früherer Reverse-Stock-Splits angepasst wurden. Die Offenlegung wurde auf einem Formular 4 von einer einzelnen meldenden Person eingereicht und enthält eine Vollmachtsbeilage.
FAQ
What change did Robert L. Ferrara report on Form 4 for PHIO?
When do the restricted stock units reported by PHIO director vest?
How many PHIO shares does the reporting person beneficially own after the transaction?
Was any cash paid for the RSUs reported on the PHIO Form 4?
Did the filing note any adjustments to reported share counts?
